XML 28 R17.htm IDEA: XBRL DOCUMENT
v3.23.2

Earnings per Common Share | 6 Months Ended
--- | ---
Jun. 30, 2023
Earnings Per Share [Abstract] |
Earnings per Common Share | Earnings per Common Share The following table sets forth the computation of basic and diluted earnings per common share (in millions, except per share amounts):
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Basic: |  |  |  |  |  |  |
Numerator: |  |  |  |  |  |  |
Income from continuing operations | $ | 118.4 |  |  | $ | 59.8 |  |  | $ | 232.7 |  |  | $ | 146.2 |
Less: Net income attributable to noncontrolling interests included in continuing operations | (25.8) |  |  | (21.9) |  |  | (51.4) |  |  | (43.9) |
Less: Income from continuing operations allocated to participating securities | (0.6) |  |  | (0.1) |  |  | (1.2) |  |  | (0.3) |
Income from continuing operations attributable to Encompass Health common shareholders | 92.0 |  |  | 37.8 |  |  | 180.1 |  |  | 102.0 |
(Loss) income from discontinued operations, net of tax | (1.2) |  |  | 11.5 |  |  | (2.2) |  |  | 35.2 |
Less: Net income attributable to noncontrolling interests included in discontinued operations | — |  |  | (0.7) |  |  | — |  |  | (1.3) |
Less: Income from discontinued operations allocated to participating securities | — |  |  | (0.1) |  |  | — |  |  | (0.2) |
(Loss) income from discontinued operations attributable to Encompass Health common shareholders | (1.2) |  |  | 10.7 |  |  | (2.2) |  |  | 33.7 |
Net income attributable to Encompass Health common shareholders | $ | 90.8 |  |  | $ | 48.5 |  |  | $ | 177.9 |  |  | $ | 135.7 |
Denominator: |  |  |  |  |  |  |
Basic weighted average common shares outstanding | 99.5 |  |  | 99.2 |  |  | 99.5 |  |  | 99.2 |
Basic earnings per share attributable to Encompass Health common shareholders: |  |  |  |  |  |  |
Continuing operations | $ | 0.92 |  |  | $ | 0.38 |  |  | $ | 1.81 |  |  | $ | 1.03 |
Discontinued operations | (0.01) |  |  | 0.11 |  |  | (0.02) |  |  | 0.34 |
Net income | $ | 0.91 |  |  | $ | 0.49 |  |  | $ | 1.79 |  |  | $ | 1.37 |
Diluted: |  |  |  |  |  |  |
Numerator: |  |  |  |  |  |  |
Income from continuing operations | $ | 118.4 |  |  | $ | 59.8 |  |  | $ | 232.7 |  |  | $ | 146.2 |
Less: Net income attributable to noncontrolling interests included in continuing operations | (25.8) |  |  | (21.9) |  |  | (51.4) |  |  | (43.9) |
Income from continuing operations attributable to Encompass Health common shareholders | 92.6 |  |  | 37.9 |  |  | 181.3 |  |  | 102.3 |
(Loss) income from discontinued operations, net of tax | (1.2) |  |  | 11.5 |  |  | (2.2) |  |  | 35.2 |
Less: Net income attributable to noncontrolling interests included in discontinued operations | — |  |  | (0.7) |  |  | — |  |  | (1.3) |
(Loss) income from discontinued operations attributable to Encompass Health common shareholders | (1.2) |  |  | 10.8 |  |  | (2.2) |  |  | 33.9 |
Net income attributable to Encompass Health common shareholders | $ | 91.4 |  |  | $ | 48.7 |  |  | $ | 179.1 |  |  | $ | 136.2 |
Denominator: |  |  |  |  |  |  |
Diluted weighted average common shares outstanding | 101.1 |  |  | 100.3 |  |  | 101.0 |  |  | 100.2 |
Diluted earnings per share attributable to Encompass Health common shareholders: |  |  |  |  |  |  |
Continuing operations | $ | 0.91 |  |  | $ | 0.38 |  |  | $ | 1.79 |  |  | $ | 1.02 |
Discontinued operations | (0.01) |  |  | 0.11 |  |  | (0.02) |  |  | 0.34 |
Net income | $ | 0.90 |  |  | $ | 0.49 |  |  | $ | 1.77 |  |  | $ | 1.36 |
The following table sets forth the reconciliation between basic weighted average common shares outstanding and diluted weighted average common shares outstanding (in millions):
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Basic weighted average common shares outstanding | 99.5 |  |  | 99.2 |  |  | 99.5 |  |  | 99.2 |
Restricted stock awards, dilutive stock options, and restricted stock units | 1.6 |  |  | 1.1 |  |  | 1.5 |  |  | 1.0 |
Diluted weighted average common shares outstanding | 101.1 |  |  | 100.3 |  |  | 101.0 |  |  | 100.2 |
See Note 17, Earnings per Common Share, to the consolidated financial statements accompanying the 2022 Form 10‑K for additional information related to our common stock.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//260/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration